{"entity":{"id":"nct07678684","kind":"trial","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","aka":[],"tldr":"A phase 2 trial of HF1K16 in glioma & glioblastoma, run by HighField Biopharmaceuticals Corporation, now recruiting.","summary":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma is a phase 2 interventional study registered as NCT07678684 by HighField Biopharmaceuticals Corporation, with 30 participants planned, started 2026-06-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: HF1K16.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07678684","url":"https://clinicaltrials.gov/study/NCT07678684"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07678684","phase":"2","setting":"A Multicenter, Open-Label, Adaptive Phase Ⅱ Clinical Study of HF1K16 Combined With Bevacizumab in Recurrent or Progressive Glioma","sponsor":"HighField Biopharmaceuticals Corporation","enrolled":30,"outcomes":[]},"route":"/trials/nct07678684/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}